CLINICAL STUDIES/TRIALS

临床研究/试验

• 批准号: 6585960
• 负责人: ALAN N. HOUGHTON
• 金额: $ 23.06万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-19 至 2003-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6585960
• 关键词: antineoplastics; chimeric proteins; cis platinum compound; clinical research; clinical trial phase I; combination cancer therapy; combination chemotherapy; doxorubicin; drug screening /evaluation; human subject; human therapy evaluation; isolation perfusion; laboratory rat; lung neoplasms; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer surgery; neoplasm /cancer vaccine; nonhuman therapy evaluation; sarcoma; vaccine development

This Clinical Studies/Trials Project is based on accomplishment over the past several years and continues to support two major initiatives (1) intensification of chemotherapy by regional Infusion" of the lung for patients with Soft Tissue Sarcoma metastatic to the lung. (2) Preclinical and clinical immunologic studies of high risk STS patients. In section 1a, phase I and phase II trials are ongoing and planned. Tissue obtained from patients in these studies will be sent to investigators in project 1b, 2, and 3 for analysis of tumor antigens, cell cycle regulators and mechanisms of drug resistance. In section 1b, preclinical studies are planned to define novel approaches for the development of tumor vaccines in order to delay or prevent progression of disease. Little is known about potential target on STS, except gangliosides and SYT_SSX fusion proteins, both under study in this Program Project. Therefore, we plan to identify antigens expressed by screening DNA libraries derived from autologous tumors, investigate peptide and DNA immunization against SYT_SSX fusion proteins, and evaluate immunizations against combinations of gangliosides in high risk patients. ?

该临床研究/试验项目是基于对 过去几年，继续支持两个主要举措（1） 通过区域输注对化学疗法的加强” 软组织肉瘤转移到肺部的患者。 （2）临床前 以及高风险STS患者的临床免疫学研究。在第1A节中 第一阶段和第二阶段试验正在进行和计划。从组织中获得的组织 这些研究中的患者将发送给项目1B，2和项目的研究人员 3用于分析肿瘤抗原，细胞周期调节剂和机制 耐药性。在第1B节中，计划定义临床前研究 为了延迟肿瘤疫苗开发的新方法 或预防疾病的进展。关于潜在目标知之甚少 在STS上，除神经毒剂和SYT_SSX融合蛋白外，都在 在此计划项目中学习。因此，我们计划识别抗原 通过筛选自体肿瘤得出的DNA文库表达， 研究针对SYT_SSX融合的肽和DNA免疫 蛋白质，并评估针对组合的免疫 高风险患者的神经节。 ？